Table 3 Comparison of 10-years observed versus ACC/AHA PCE-predicted risks of ASCVD events in South Asian adults, stratified by statin exposure status
AHA/ACC PCE 10-years predicted risk category | Composite outcome of myocardial infarction, stroke and presumed cardiovascular death | ||||||
|---|---|---|---|---|---|---|---|
N | Predicted events (N) | Observed events (N) | Mean predicted risk (%) | Observed risk (%) | Relative risk (predicted: observed) | p | |
Never user of statins (n = 773) | |||||||
Low (< 5.0%) | 621 | 8.5 | 13 | 1.4 | 2.1 | 0.67 | 0.12 |
Borderline (5.0 to < 7.5%) | 53 | 3.2 | 5 | 6.1 | 9.4 | 0.65 | 0.32 |
Intermediate (7.5 to < 20.0%) | 89 | 10.6 | 14 | 12.0 | 15.7 | 0.76 | 0.27 |
High (≥ 20.0%) | 10 | 2.6 | 4 | 25.5 | 40.0 | 0.64 | 0.29 |
Initiated statin therapy during follow-up only (n = 688) | |||||||
Low (< 5.0%) | 399 | 8.7 | 31 | 2.2 | 7.8 | 0.28 | < 0.001 |
Borderline (5.0 to < 7.5%) | 92 | 5.7 | 8 | 6.2 | 8.7 | 0.71 | 0.32 |
Intermediate (7.5 to < 20.0%) | 161 | 19.2 | 20 | 11.9 | 12.4 | 0.96 | 0.84 |
High (≥ 20.0%) | 36 | 9.7 | 12 | 26.9 | 33.3 | 0.81 | 0.38 |
Received statin therapy at entry and during follow-up (n = 374) | |||||||
Low (< 5.0%) | 166 | 4.3 | 14 | 2.6 | 8.4 | 0.31 | < 0.001 |
Borderline (5.0 to < 7.5%) | 46 | 2.9 | 6 | 6.2 | 13.0 | 0.48 | 0.05 |
Intermediate (7.5 to < 20.0%) | 118 | 14.3 | 18 | 12.1 | 15.3 | 0.79 | 0.30 |
High (≥ 20.0%) | 44 | 12.2 | 14 | 27.6 | 31.8 | 0.87 | 0.53 |